Rigel Pharmaceuticals, Inc. (RIGL)
A Look At The Transformation Around Rigel Pharmaceuticals
Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing strong Tavalisse performance and recent product acquisitions. Q1 revenues rose 10% year-over-year to $58.8 million, but net product revenues rose 26%; management also maintained FY2026 sales guidance of $275–$290 million.
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.63 per share a year ago.
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock?
Investors need to pay close attention to RIGL stock based on the movements in the options market lately.
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Rigel Pharmaceuticals (RIGL) is upgraded to a speculative Buy as profitability and product momentum improve. Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's market cap. Tavalisse demand surged, carving a defensible niche in ITP; Rezlidhia seeks expansion beyond AML.
Rigel Pharmaceuticals: Growing Where It Matters
Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies, justifying a continued Buy rating. RIGL trades at a low P/E of ~7 despite robust 2025 revenue growth and positive cash flow, suggesting undervaluation relative to peers. Pipeline risk remains, as R289 for lower-risk MDS is still early-stage and highly speculative, with no imminent label expansions for existing drugs.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.8 per share a year ago.
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven primarily by the lead marketed drug Tavalisse.
